Cidara Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
6.50
|
|
Average Rating
|
4.50
|
|
# Strong Buys
|
2
|
|
# Buys
|
2
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
0.18
|
0.17
|
-0.01
|
-5.56%
|
|
2022-06-30
|
-0.28
|
-0.19
|
0.09
|
32.14%
|
|
2022-03-31
|
-0.29
|
-0.27
|
0.02
|
6.90%
|
|
2021-12-31
|
-0.34
|
-0.26
|
0.08
|
23.53%
|
|
2021-09-30
|
-0.36
|
-0.37
|
-0.01
|
-2.78%
|
|
2021-06-30
|
-0.08
|
0.18
|
0.26
|
325.00%
|
|
2021-03-31
|
-0.26
|
-0.39
|
-0.13
|
-50.00%
|
|
2020-12-31
|
-0.24
|
-0.49
|
-0.25
|
-104.17%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-0.29
|
|
2021-12-31
|
-0.84
|
|
2020-12-31
|
-1.81
|
|
2019-12-31
|
-1.43
|
|
2018-12-31
|
-2.86
|
|
2017-12-31
|
-3.21
|
|
2016-12-31
|
-3.32
|
|
2015-12-31
|
-7.90
|